Nektar Therapeutics

/UPDATE -- Nektar Therapeutics/

Nektar Therapeutics presented long-term Phase 2b data on rezpegaldesleukin at the EADV Congress 2026 showing durable and deepening responses in alopecia areata and atopic dermatitis through 52 weeks and off-treatment follow-up. In alopecia areata, 75% of patients maintained SALT Score ≤20 four months off treatment and 63% at six months, while SALT ≤10 responses deepened from 7% to 19% after six months off therapy. In atopic dermatitis, monthly and quarterly maintenance dosing sustained EASI-75/EASI-90 responses, with EASI-100 rates rising from 4% to 22% (Q4W) and 9% to 18% (Q12W) between Weeks 16 and 52. Nektar has initiated a third Phase 3 ZENITH AD study in treatment-experienced patients and will start the 850-patient Phase 3 ZENITH AA study in early 2027.

•1mo ago

New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis

Nektar Therapeutics presented new multi-omic biomarker data from the Phase 2b REZOLVE-AD study at EADV Congress 2026, showing rezpegaldesleukin drives Treg-mediated immune changes as early as Week 2. Early biomarker changes were significantly correlated with Week 16 clinical improvement only in rezpegaldesleukin-treated patients (p<0.001), with a 64% mean EASI reduction in the molecular cohort versus 61% in the overall 24 µg/kg Q2W cohort. The data strengthen confidence in the drug's differentiated mechanism as the program advances into Phase 3, supporting its 'pipeline in a product' positioning across atopic dermatitis, alopecia areata, and Type 1 diabetes.

•1mo ago

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Therapeutics announced three oral presentations of Phase 2b rezpegaldesleukin data at the EADV Congress 2026 in Vienna, September 30 to October 3. The highlight is new 6-month (24-week) off-treatment data from the 92-patient REZOLVE-AA study evaluating durability of response in severe-to-very-severe alopecia areata, completed in September 2026. The company will host an investor call on October 1, 2026 at 8:00 AM ET to discuss the new data, joined by Mount Sinai's Dr. Benjamin Ungar. Data remain under embargo until September 30, so the actual efficacy readout is still ahead; rezpegaldesleukin holds FDA Fast Track designations in both atopic dermatitis and alopecia areata.

•1mo ago

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics announced the publication of positive Phase 2b data for rezpegaldesleukin in moderate-to-severe atopic dermatitis in The Lancet. The REZOLVE-AD study met all primary and key secondary endpoints, with the high-dose regimen achieving a 61% mean reduction in EASI scores compared to 31% for placebo. The drug demonstrated statistically significant improvements across multiple measures including EASI-75, EASI-90 and itch NRS, while showing a favorable safety profile with no increased risk of infections. These results support the mechanism of T-reg modulation and the selected dosing regimen for the ongoing Phase 3 ZENITH AD program. The registrational Phase 3 program includes three global trials currently enrolling or initiating, with a separate trial planned for alopecia areata in early 2027.

•2mo ago

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Nektar reported Q2 revenue of $10.1 million, down from $11.2 million a year ago, with a net loss of $40.6 million or $1.23 per share. The company's financial position strengthened significantly, with cash and investments rising to $1.02 billion from $245.8 million at year-end 2025, extending its cash runway into Q3 2028. The company initiated the first Phase 3 ZENITH AD trials for its lead program rezpegaldesleukin in atopic dermatitis in July, with plans to start a registrational study in alopecia areata in early 2027. Management confirmed the path to a BLA submission in 2029, citing the novel T-reg mechanism and strong financial position as key enablers for advancing the clinical program.

•2mo ago

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics initiated the first two global registrational Phase 3 trials (ZENITH AD-1 and AD-2) for rezpegaldesleukin in moderate-to-severe atopic dermatitis, targeting 1,530 patients total across the program. The Phase 3 design follows successful End-of-Phase 2 meetings with the FDA and EMA and is supported by clinically meaningful efficacy data in the 393-patient Phase 2b study. Initial topline data is expected in mid-2028 with a BLA submission targeted for 2029, while a separate Phase 3 trial in alopecia areata is planned for early 2027.

•3mo ago

Nektar Therapeutics Reports First Quarter 2026 Financial Results

Nektar Therapeutics reported Q1 2026 financial results with $10.9 million in revenue and a net loss of $44.9 million. The company's cash and investments in marketable securities on March 31, 2026, were $731.6 million, excluding $351 million in net proceeds from a secondary offering completed in April 2026. Nektar highlighted clinical progress for its lead candidate rezpegaldesleukin, including initiation of the Phase 3 ZENITH-AD program in atopic dermatitis by July 2026 and an End-of-Phase 2 meeting with the FDA for alopecia areata this quarter.

•5mo ago